Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Probiotic treatment does not benefit infants with colic

This week's issue of the British Medical Journal examines treating infant colic with the probiotic Lactobacillus reuteri.

News image

Dr Valerie Sung and colleagues from Australia determined whether the probiotic Lactobacillus reuteri DSM 17938 reduces crying or fussing in a broad community based sample of breastfed infants and formula fed infants with colic aged less than 3 months.

The research team performed a double blind, placebo controlled randomized trial.

The team evaluated 167 breastfed infants or formula fed infants aged less than 3 months meeting Wessel’s criteria for crying or fussing.

The team randomized 85 to receive probiotic, and 82 to receive placebo.

At 1 month, the probiotic group cried or fussed 49 minutes more than the placebo group
British Medical Journal

Interventions included oral daily Lactobacillus reuteri versus placebo for 1 month.

The team's primary outcome was daily duration of cry or fuss at 1 month.

Secondary outcomes were duration of cry or fuss, number of cry or fuss episodes, sleep duration of infant at 7, 14, and 21 days, and 1 and 6 months, maternal mental health, family functioning, parent quality adjusted life years at 1 and 6 months, infant functioning at 6 months, infant fecal microbiota, and calprotectin levels at 1 month.

In intention to treat analyses the 2 groups were compared using regression models adjusted for potential confounders.

The team reported that of 167 infants randomized from 2011 to 2012, 76% were retained to primary outcome.

Of these, a subset was analyzed for fecal microbial diversity, E coli colonization, and calprotetectin levels.

The team observed that adherence was high.

Mean daily cry or fuss time fell steadily in both groups.

The team found that at 1 month, the probiotic group cried or fussed 49 minutes more than the placebo group.

This mainly reflected more fussing, especially for formula fed infants.

The researchers found that groups were similar on all secondary outcomes.

No study related adverse events occurred.

Dr Sung and colleagues conclude, "Lactobacillus reuteri DSM 17938 did not benefit a community sample of breastfed infants and formula fed infants with colic."

"These findings differ from previous smaller trials of selected populations, and do not support a general recommendation for the use of probiotics to treat colic in infants."

BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g2107
10 April 2014

Go to top of page Email this page Email this page to a colleague

 02 March 2015

Advanced search
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 02 March 2015 
Liver disease in patients awaiting liver transplant
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 13 February 2015 
Prevalence of microscopic colitis
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patients’ colonoscopist selection
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us